Abstract
Depression in Parkinson's Disease is Associated with a Serotoninergic System Change Secondary to Neuroinflammation
Highlights
Depression is a common psychiatric disorder in patients with Parkinson’s disease (PD), being more prevalent in PD than in any other chronic disabling disease. [1]
The dopaminergic and serotonergic neurotransmitter systems are involved in regulating mood, and changes in these systems are associated with depression in the general population and in patients with neurodegenerative diseases like PD [5]
Traditional nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin (ASA) inhibit both isoforms and selective NSAIDs preferentially inhibit COX2 [50]. Studies suggest that both isoforms are unevenly distributed among cells of the central nervous tissue, COX-1 being detected in microglial cells and COX-2 found primarily in glial cells, and at lower levels, in the dopaminergic neurons of the substantia nigra pars compacta (SNpc) [52]
Summary
Depression (depressive disorder) is a common psychiatric disorder in patients with Parkinson’s disease (PD), being more prevalent in PD than in any other chronic disabling disease. [1]. The idea that activation of the HPA axis in response to chronic stress induces changes in the hippocampal serotonergic system, predisposing the individual to the development of depression [27,28].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: International Journal of Neurology and Neurotherapy
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.